MIAMI, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has completed an initial capital raise from Retrograde Investments LLC. The proceeds from the investment will be used to fund the costs associated with bringing current all financial audits and filings and maintaining SEC compliance, as well as help support the company’s initial clinical trials for its prospective COVID-19 therapeutic treatment.

Albert Mitrani, Chief Executive Officer of Organicell stated, “With this initial capital infusion, combined with the exciting results from our initial eIND trials, we are anticipating an exciting remainder of 2020. We look forward to completing our audit and providing shareholders with further visibility into our continued clinical trials and product development plans in the near future.”

About Organicell Regenerative Medicine, Inc.:

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.

About Retrograde Investments, LLC

Retrograde Investments, LLC is a small family office focused on derivatives trading and opportunistic investments.